Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610048 · ClinicalTrials.gov registry record · Phase 3
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Alkermes.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT03610048 is a Phase 3 study that was terminated before completion, run by Alkermes. The registered enrollment target is 175 participants.
The verdict
NCT03610048, a Phase 3 study, was terminated before completion, sponsored by Alkermes.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
Interventions
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2020-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610048
The ClinicalTrials.gov registry entry for NCT03610048 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALKS 5461 is the first listed.
NCT03610048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03610048 about?
NCT03610048 is a clinical study titled "A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)". This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
What is the current status of trial NCT03610048?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2018-08-09. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT03610048?
The interventions under investigation include: ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT03610048?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.